“GLP-1 Therapies Enter the CKM Guideline For the First Time, GLP-1-Based Therapy Is Recommended to Reduce Cardiac Events”. Diabzen, vol. 4, no. 18, July 2026, pp. 36-37, https://thediabzen.com/index.php/d/article/view/61.